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Abstract
We have examined whether epigallocatechin-3-gallate (EGCG), and extract of green tea, in combination with taxane
(i.e., paclitaxel and docetaxel), exerts a synergistic activity in blocking human prostate PC-3ML tumor cell growth
in vitro and in vivo. Growth assays in vitro revealed that the IC50 values were ∼30 μM, ∼3 nM, and ∼6 nM, for
EGCG, paclitaxel and docetaxel, respectively. Isobolograms generated from the data clearly indicated that EGCG in
combination with paclitaxel or docetaxel had an additive effect in blocking tumor cell growth. EGCG combined with
taxane also had an additive effect to increase the expression of apoptotic genes, (p53, p73, p21, and caspase 3)
and the percent apoptosis observed in vitro and in tumor modeling studies in severe combined immunodeficient
mice. The tumor modeling studies clearly showed that EGCG plus taxane injected intraperitoneally (i.p.) induced a
significant increase in apoptosis rates (TUNEL assays) and eliminated preexisting tumors generated from PC-3ML
cells implanted i.p., increasing disease-free survival rates to greater than 90%. More importantly, the combination
therapy (i.p. biweekly) blocked metastases after intravenous injection of PC-3ML cells through the tail vein. In mice
treated with EGCG plus taxane, the disease-free survival rates increased from 0% (in untreated mice) to more than
70% to 80% in treated mice. Taken together, these data demonstrate for the first time that EGCG in combination
with taxane may provide a novel therapeutic treatment of advanced prostate cancer.
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Introduction
Prostate cancer is the most commonly diagnosed neoplasm in men,
accounting for approximately 29% of all of new cancers. In 2000,
an estimated 180,400 men will be diagnosed with prostate cancer,
and approximately 32,000 will die [1]. Surgery and radiation ther-
apy (external beam or brachytherapy seed implantation) remain the
most common therapeutic modality for the treatment of clinically
localized prostate cancer [2]. Once prostate cancer enters a metastatic
stage, the current treatment is androgen ablation therapy, which pro-
vides relief from otherwise uncontrollable bone pain and increases
life expectancy by 6 to 18 months in 70% of men [3]. For many
years, it was felt that chemotherapy did not play any role in the treat-
ment of advanced prostate cancer. However, this negative impression
may be starting to change because activity is being seen with new
drugs and drug combinations [4] and in particular with the use of
docetaxel [5].
We have previously carried out animal model studies with purified
epigallocatechin-3-gallate (EGCG) [6]. The animal studies have
demonstrated that the continuous intraperitoneally (i.p.) administra-
tion of EGCG at a dose of 200 μM/animal (228 mg/kg) every 3 days
can significantly reduce distant prostate tumor xenograft growths in
CB17 severe combined immunodeficient (SCID) mice [6]. In the
past 10 years, EGCG has entered phase 1/2 clinical trials for the
treatment of leukemia and lung cancer [7,8].
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Although conventional cancer therapies (surgery, chemotherapy,
and radiation) are often effective at curing early stage disease, few
human metastatic cancers are curable with a single modality, and
the death rate from metastatic prostate cancer has not decreased sig-
nificantly in the past 30 years. In an attempt to widen the curative
therapeutic window of EGCG, we explored a neoadjuvant therapy
that consisted of combining EGCG with chemotherapeutic agents
such as doxorubicin and showed that EGCG increased the therapeu-
tic efficacy of doxorubicin in vivo [6].
In the present study, we examined the efficacy of EGCG in com-
bination with taxane (paclitaxel and docetaxel) against human pros-
tate cancer cells. Synergistic efficacy was observed both in vitro and
in vivo. The in vitro studies revealed that EGCG plus taxane had an
additive effect in blocking tumor cell growth and inducing apoptosis
of PC-3ML cells. The in vivo tumor modeling studies showed that
the combination of EGCG (200 μM or 228 mg/kg) with docetaxel
(i.e., at therapeutic doses effective in humans) eliminated PC-3ML
xenografts within 5 to 6 weeks and increased mouse survival rates
by more than 90%. In addition, EGCG plus paclitaxel blocked bone
metastases by PC-3ML cells injected intravenously (i.v.) through the
tail vein and increased mouse survival rates from 0% in untreated
mice to more than 70% to 80% in treated mice. Taken together,
these results suggest that EGCG used in combination with taxane
can offer a curative therapeutic approach for eradication of primary
tumors and metastatic prostate cancer.
Materials and Methods
Cell Cultures
PC-3ML cells were previously isolated as single cell clones derived
from bone marrow metastases by PC-3 cells in CB17 SCID mice [9].
The PC-3ML cultures were maintained in Dulbecco modified Eagle
medium (DMEM) plus 10% fetal bovine serum according to previ-
ously described protocols of the American Tissue Culture Collection
(Bethesda, MD) [9].
MTT Assays of Cell Growth/Viability
Growth and cell viability assays were carried out using 3-[4,5-
dimethylthiazole-2-4]-2,5-diphenyl-2H -tetrazolium bromide (MTT).
PC-3ML cells were seeded at 5000 cells/well in 96-well plates (Falcon;
Discovery Labware, Bedford, MA) for 24 hours before treatment with
the drug. The MTTassays were carried out as described previously by
our group [6]. Cells were treated either with EGCG, paclitaxel, or
docetaxel or with EGCG in combination with paclitaxel or docetaxel.
Cell growth (Figure 1, A and B) and cell viability (Figure 1, C–G) were
measured at the times indicated by removing the medium and replac-
ing it with DMEM containing 1 mg/ml MTT (Sigma Chemical Co,
St Louis, MO) (100 μl of MTT for 3 hours at 37°C). For the growth
assays, the plates were read on a Microtiter Plate Reader (A490 nm)
(Molecular Dynamics, Sunnyvale, CA) [6]. For cell viability assays,
the MTT solution was removed, and the crystals that remained in
the wells were solubilized by the addition of 50 μl of isopropanol
followed by vigorous shaking [10]. The absorbency was determined
using a microplate reader (Molecular Dynamics) at 560 nm (test
wavelength) and 690 nm (reference wavelength). The percentage of
surviving cells was estimated by dividing the A550 nm − A650 nm
of treated cells by the A550 nm − A650 nm of mock-treated cells [10].
Twelve replica samples were taken for each time point, and each ex-
periment was repeated at least three times.
Apoptosis Assays
Apoptosis was measured by flow cytometry using Annexin V anti-
bodies and a kit from Guava, Inc (Redwood, CA) according to pub-
lished methods by our group [11]. TUNEL assays were carried with
antibodies from Sigma using established protocols [11].
Gel Electrophoresis and Western Blots
Cultured cells or cells isolated from tumors by collagenase I diges-
tion (100 ng/ml for 30 minutes) were lysed with modified RIPA buffer
[11]. Protein measurements were carried out according to Sambrook
and Russell [12], and crude extracts prepared for SDS-PAGE and
electroblotted onto Hybond enhanced chemiluminescence membranes
(Amersham Pharmacia, Buckinghamshire, England) according to
standard procedures [12]. Western blots were carried out according
to standard procedures [11,12] using Super Signal West Pico chemi-
luminescent substrate (Pierce Biotechnology, Inc, Rockford, IL) for
antibody detection. The reaction was visualized using the ChemiDoc
XRS Gel Documentation system and band densities analyzed by
Multi-Analyst software (Bio-Rad Laboratories, Inc, Hercules, CA).
Antibodies specific for p53, p71, p21, caspase 3, and β-actin were pur-
chased from Sigma-Aldrich.
Drug Studies
EGCG (Sigma-Aldrich) was prepared fresh by resuspension of
EGCG in PBS, pH 5, containing 3% ascorbic acid, and 10mMEDTA
(the solvent). The EGCG solution was filter sterilized and added to cells
or injected in mice. Paclitaxel (Taxol; Bristol-Myers Squibb, Princeton,
NJ) and docetaxel (Taxotere; Rhone-Poulenc Rorer Pharmaceuticals,
Inc, Collegeville, PA) were solubilized in 50% dimethylsulfoxide and
aliquots of the stock solutions diluted with DMEM for in vitro studies
and with 0.9% NaCl for in vivo studies.
The IC50 was defined as the concentration of drug that produced
50% cell growth inhibition, that is, 50% reduction in absorbance in
MTT growth assays. The dose-response curves were plotted with
CurveExpert (Version 1.34) on a semilog scale as a percentage of
the control, the absorbance of which was obtained from the samples
not exposed to the drugs. On the basis of the dose-response curves of
EGCG alone and taxane alone, isobolograms (three isoeffect curves,
mode 1 and mode 2 lines) were computed. The envelope of additiv-
ity, surrounded by mode 1 and mode 2 isobologram lines, was con-
structed from the dose-response curves of EGCG alone and taxane
alone. The observed data were compared with the predicted maxi-
mum and minimum data for the presence of synergism, additivity,
or antagonism by a statistical analysis using the Stat View 4.01 soft-
ware program (Abacus Concepts, Berkeley, CA). When the data
points of the drug combination fall within the area surrounded by
mode 1 and/or mode 2 lines (i.e., within the envelope of additivity),
the combination is described as additive. A combination that gives
data points to the left of the envelope of additivity can be described
as supra-additive (synergism), and a combination that gives data
points to the right of the envelope of additivity can be described as
subadditive (antagonistic [13]).
Tumor Xenografts in CB17 SCID Mice
Methods previously described by our group were used to develop
xenograph tumors i.p. [6]. In brief, single-cell suspensions of PC-
3ML cells (1 × 106 cells) at less than passage 10 were injected i.p.
in 5- to 6-week-old CB17 SCID mice (Taconic Labs, Pottstown,
NY). When tumors reached a minimal volume of 0.15 to 0.18 mm3
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Figure 1. (A–C) MTT growth assays with PC-3ML cells. (A) Cells were treated with 0 to 12 nM paclitaxel or docetaxel for 8 days. IC50
values were ∼3 nM docetaxel and ∼6 nM paclitaxel, respectively. (B) Cells were treated with 0 to 80 μM EGCG for 8 days. The IC50 was
∼30 μM EGCG. (C) Cells were treated with vehicle (mock), EGCG (30 μM), paclitaxel (6.25 nM), docetaxel (3.12 nM), EGCG (30 μM) plus
paclitaxel (6.25 nM), and EGCG (30 μM) plus docetaxel (3.12 nM) for 8 days. (A–C) Cells were seeded at ∼25% confluence in 96-well
plates overnight before beginning the drug treatments. In combination drug studies, cells were exposed to EGCG plus taxane with
changes of medium every 2 days. Values represent the mean ± SD from three experiments. (D–G) MTT growth assays with PC-3ML
cells treated with EGCG (30 μM), paclitaxel (6.25 nM), docetaxel (3.12 nm), or a combination of these drugs at these concentrations.
(D) Shows the decrease in cell viability of PC-3ML cells treated with EGCG (x) 30 μM and (*) 50 μMplus paclitaxel (6.25 nm). (E) Isobologram
analysis of the observed data for the combination of EGCG and paclitaxel shown in D. (F) Decrease in cell viability of PC-3ML cells
treated with EGCG (x) 30 μM and (*) 50 μM plus docetaxel (3.12 nm). (G) Isobologram analysis of the observed data for the combination
of EGCG and docetaxel in F. The concentration that produced 50% cell growth inhibition (IC50) is expressed as 1.0 in the ordinate and the
abscissa of the isobologram. y axis, EGCG (IC50); x axis, paclitaxel or docetaxel (IC50).
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(after ∼1 week), drug was injected i.p. in a volume of 0.50 ml per
mouse. Each group had 5 or 10 mice, and tumor volumes were deter-
mined bymeasurement of tumor length (L) and width (l ) with a caliper
and calculated according to the formula: (L × l 2) / 2.
Bone metastases studies were carried out according to published
methods by our group [9]. In brief, PC-3ML cells were injected i.v.
through the tail veil in 0.1 ml of DMEM. Once tumors had been
allowed to establish for 1 or 2 weeks, mice were treated with drug
injected i.p. according to the above approach. Mice were kept in a
double-barrier facility and handled according to an approved Institu-
tional Animal Control Use Committee protocol in accordance with
our institution’s policy.
Effects of Drug on Established Tumors
PC-3ML xenografts were established as described [6]. Mice that
bore tumors were randomized into groups of four. The first group
received 200 μM of EGCG (228 mg/kg) at day 1. EGCG was in-
jected i.p. using a 28-gauge needle on a weekly basis. The second
group was given taxane only. Paclitaxel was administered i.p. at a dose
of 15 mg/kg weekly. Docetaxel was administered i.p. at a dose of 5 or
12.5 mg/kg i.p. weekly. The third group was given EGCG (i.p.) at
day 1 and taxane at the same doses and schedule as the second group.
As a control (vehicle), a fourth group was treated with 0.1 ml of nor-
mal saline (i.e., control) i.p.
For docetaxel, the dose was selected based on the human clinical
dose (Rhone-Poulenc Rorer Pharmaceuticals, Inc) and determined by
a dose range–finding study in nude mice [14]. Tumor volumes were
measured as described previously [6].
Immunohistochemistry
Four groups of mice (n = 5) were treated with vehicle, EGCG
(200 μM/animal or 228 mg/kg), paclitaxel (15 mg/kg), or a combi-
nation of EGCG and paclitaxel. Half of the animals were killed on
day 9 and the other half on day 16. Histology methods were as
described previously [6]. Apoptotic cells were detected using the
TUNEL assay [6,12]. Paraffin-embedded tumor sections were heated
in citric acid buffer for 15 minutes to retrieve antigen, hybridized
with the TUNEL antibody, then counterstained with Harries hema-
toxylin (Roche Molecular Biochemicals, Mannheim, Germany). The
stained sections were analyzed under a light microscope, and the
numbers of apoptotic cells were counted in five fields of view from
three different tumors.
Statistical Analysis
Significant changes were assessed by Student’s t test. The results
are presented as the mean ± SD. P < .05 was accepted as the level
of significance. The dose-response interactions between taxane and
EGCG at the point of IC50 were evaluated by the isobologram method
of Steel and Peckham [15] as modified by Aoe et al. [16].
Results
Combination of EGCG with Paclitaxel or Docetaxel Inhibits
Growth of PC-3ML Cells in a Synergistic Manner
Growth assays were carried out to assess the potential synergistic
activities of EGCG in combination with paclitaxel or docetaxel on
the proliferation of malignant human prostate PC-3ML cells (Figure 1,
A–C). The dose-response curves indicated that the IC50 values were
∼6 nM paclitaxel, ∼3 nM docetaxel, and ∼30 μM EGCG after treat-
ment of the cells with increased dosages of each agent for 8 days
(Figure 1, A and B). Growth assays further showed that EGCG
(30 μM) in combination with either paclitaxel (6.25 nM) or docetaxel
(3.12 nM) exhibited a synergistic activity in reducing growth rates to
near zero by ∼2 to 8 days (Figure 1C). Likewise, cell viability assays
further demonstrated that the combination of EGCG (30 and 50 μM)
with paclitaxel (6.25 nM) reduced cell survival to zero after ∼6 to
10 days (Figure 1D).
Isobolograms were generated from the models to determine the pres-
ence of synergy, additivity, or antagonism between EGCG and paclitaxel.
Figure 1E shows isobologram representation of the statistical modeling
used to analyze the drug interactions between two dosages of EGCG
(0, 30, and 50 μM) and paclitaxel (6.3 nM). The combined data points
fell within the envelope of additivity or were smaller than that of the
predicted minimum data, which indicates that sequential exposure to
EGCG for 24 hours followed by EGCG plus paclitaxel produced syner-
gistic effects by ∼6 to 10 days (Figure 1E).
Enhanced cytotoxicity was also observed in the combination treat-
ment of EGCG and docetaxel. Cell viability assays revealed that
EGCG (30 μM) or docetaxel (3.12 nm) alone produced more than
80% cell survival of prostate carcinoma PC-3ML cells after 2 to
8 days treatment (Figure 1F). In comparison, EGCG at (x) 30 μM
and (*) 50 μM combined with docetaxel (3.12 nm) reduced cell via-
bility to less than 10% after 5 to 8 days treatment (Figure 1F ).
Isobologram representation of the statistical modeling used to ana-
lyze the interaction between EGCG and docetaxel revealed that the
combined data points fell to the left of the envelope of additivity,
or, restated, the IC50 of EGCG in combination with docetaxel oc-
curred at smaller doses than that predicted from the use of EGCG
or docetaxel alone by 6 to 10 days (Figure 1G ). Thus, exposure to
EGCG combined with docetaxel produced synergistic effects in the
inhibition of PC-3ML growth.
Combination of Taxane and EGCG Increases p53, p73, p21,
and Caspase 3 Expression
We have examined the effect of these drugs alone and in combi-
nation on the expression of apoptotic-related protein markers in at-
tempts to address the potential mechanisms, which account for the
synergistic activity of the combined drug therapy. The PC-3ML cells
were treated with the individual agents and with EGCG (30 μM)
plus docetaxel (3.12 nm) or paclitaxel (6.25 nm) for 0, 12, 24,
and 48 hours. Western blots showed that the combination of EGCG
and docetaxel or EGCG plus paclitaxel induced significant increases
in p53 and p73 expression after 12, 24, and 48 hours. In compar-
ison, EGCG and docetaxel alone had little or no effect on p53 ex-
pression after 12 and 24 hours, albeit they both induced expression
after 48 hours (Figure 2A). Paclitaxel alone failed to induce ex-
pression of p53 after 12, 24, and 48 hours, however. Interestingly,
EGCG, docetaxel, and paclitaxel alone induced p73 expression after
12 to 48 hours. Similarly, Western blots with p21 and caspase 3 anti-
bodies showed that EGCG plus docetaxel or EGCG plus paclitaxel
combined induced a significant increase in the expression of these
two proteins after 24 and 48 hours of treatment (Figure 2B). In com-
parison, the individual agents had a significantly reduced effect on
the levels of p21 and caspase 3 expression after 24 and 48 hours
(Figure 2B). Note that the vehicle failed to induce increased expres-
sion of p53, p73, p21, or caspase 3 (Figure 2, A and B). Densitomet-
ric scans of the Western blots and calculations of the fold change
in the antigen/actin ratio demonstrated that EGCG plus paclitaxel
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and EGCG plus docetaxel induced more than 2-fold and more than
1.5-fold increases in p53 and p73, respectively, after 12 and 24 hours
(i.e., compared with cells exposed to EGCG alone). Likewise, the
combined drug treatments induced more than 0.5-fold increases in
p21 and caspase 3 after 12 and 24 hours of treatment (Figure 2C ).
In comparison, the individual agents induced only small increases in
expression of these proteins. Taken together, the data suggest that
EGCG plus taxane induced genes associated with apoptosis.
EGCG in Combination with Taxane Can Increase
Apoptosis Rates
Assays were then carried out using flow cytometry with annexin V
antibodies to assess whether EGCG and taxane had a synergistic ac-
tivity in promoting apoptosis of PC-3ML cells. The percent apopto-
sis was measured after increased time intervals of 0 and 6 hours and
after 1, 2, 4, 6, and 8 days, respectively (Figure 3). The data showed
that treatment of PC-3ML cell with EGCG (30 μM) combined with
either paclitaxel (6.25 nM) or docetaxel (3.12 nM) resulted in more
than 25% apoptosis after 6 hours, 1 day, and 2 days compared with
∼6% to 10% apoptosis in the presence of the individual agents alone
(Figure 3). However, the percent apoptosis observed decreased to less
than 10% in the presence of EGCG and taxane or the individual
agents alone after 6 to 8 days (Figure 3). Note that higher EGCG
levels (50 μM) alone induced more than 10% apoptosis after 6 hours
to 4 days compared with less than 8% apoptosis observed in the pres-
ence of 30 μM EGCG (Figure 3), indicating that higher dosages of
EGCG may be more efficacious.
Therapeutic Efficacy of EGCG Combined
with Taxane In Vivo
The antitumor activities of EGCG in combination with taxane
was assessed in the PC-3ML mouse xenograft model. We have shown
previously that PC-3ML cells injected i.p. (1 × 106 cells in 1 ml)
rapidly form tumors after ∼2 week (i.e., >0.5 cm3) [6]. In mice re-
peatedly dosed i.p. with EGCG at 200 μM (228 mg/kg) biweekly
(starting at week 1), tumor growth was reduced significantly and
mouse survival rates increased dramatically from 5 to 6 weeks to
more than 3 months [6]. Unfortunately, EGCG (228 mg/kg) alone
Figure 2. (A)Western blots of p53 and p73 expression in PC-3ML cells subjected to EGCG (30 μM), docetaxel (3.12 nM), paclitaxel (6.25 nM),
and vehicle treatments alone and with (E + D) EGCG (30 μM) plus docetaxel (3.12 nM) and (E + P) EGCG (30 μM) plus paclitaxel (6.25 nM)
for 0, 12, 24, and 48 hours. Control cells were treated with vehicle. (B) Western blots with p21 and caspase 3 antibodies of crude extracts
fromPC-3ML cells treatedwith EGCG (30 μM), docetaxel (3.12 nM), paclitaxel (6.25 nM), and a combination of EGCG+docetaxel or EGCG+
paclitaxel at these same dosages for 0, 24, and 48 hours. (A and B) Cells were∼70% confluent at the time of initiation of treatments. Con-
trol blots were with β-actin antibodies. (C) Calculations of the ratio of protein/actin based on densitometric scans of Western blots for p53,
p73, p21, and caspase 3. PC-3ML cells at ∼70% confluence were treated with EGCG, docetaxel, paclitaxel, EGCG + paclitaxel, EGCG +
docetaxel at dosages shown in B for 0, 12, and 24 hours, respectively. Data represent the mean ± SD of measurements from three inde-
pendent experiments.
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only slowed growth of established tumors (i.e., 0.5 cm3). In this
study, we have examined whether tumors established i.p. could be
eliminated or reduced in size with treatments of EGCG and taxane
combined. For these experiments, established human prostate tu-
mors (PC-3ML cells) of ∼0.5 cm3 were treated with vehicle, EGCG
(200 μM/animal), paclitaxel (20 mg/kg), or both EGCG and pacli-
taxel for 9 weeks by i.p. injection on a weekly basis.
Measurements of tumor volumes after 1 to 9 weeks showed that
there was a significant decrease in tumor volume compared with the
controls (vehicle) in mice treated with EGCG (200 μM, 228 mg/kg)
plus paclitaxel (20 mg/kg) after 2, 3, 4, 5, and 6 to 9 weeks, re-
spectively (i.e., >67%, 85%, 96%, 99%, and 100%, respectively)
(Figure 4A). Likewise, similar results were observed in mice treated
with EGCG plus docetaxel (12.5 mg/kg) (data not shown). In com-
parison, in the presence of EGCG alone, tumor growth was not re-
duced after 2 to 3 weeks but was reduced to near zero after prolonged
intervals of 4 to 9 weeks of treatment. Paclitaxel (or docetaxel) alone
also reduced tumor growth rates to near zero at all stages of the ex-
periment (Figure 4A). However, EGCG, paclitaxel, or docetaxel did
not independently reduce tumor volumes significantly or eradicated
tumors (Figure 4A). Overall, comparisons of the combined therapy
to EGCG or paclitaxel (or docetaxel) alone indicated that the effects
of EGCG plus paclitaxel were statistically significant (P > .05).
The combination drug therapy studies were expanded to determine
whether increased dosages of EGCG in combination with docetaxel
(12.5 mg/kg) might increase efficacy. We found that with increased
dosages of EGCG (i.e., in a range of 100-300 μM), the antitumor
activity increased significantly at dosages of 200 to 300 μM EGCG
compared with the lower dosages of 100 μM EGCG tested (P >
.05) (Figure 4B). In fact, EGCG at concentrations greater than 200
to 300 μM (i.e., in combination with docetaxel) seemed to eliminate
the tumors after 5 to 8 weeks (Figure 4B). Finally, mouse survival stud-
ies showed that mice normally died of tumor burden after 9 weeks
treatment with EGCG or taxane alone, but less than 10% of the mice
exhibited tumors or died in the groups treated with EGCG plus taxane
for 8 weeks followed by discontinuation of the treatment for an addi-
tional 12 weeks (Figure 4C ).
Expression of p53, p73, and p21 In Vivo
Western blots showed that freshly established PC-3ML tumors (i.e.,
2 weeks after inoculation of mice i.p.) normally expressed little or no
p53, p73, and p21 protein (Figure 5). However, after treatment of the
mice with daily injections i.p. of EGCG, paclitaxel, or docetaxel alone,
the expression of p53 and p73 was induced to more than one-fold,
three-folds, and five-folds, respectively, by each of these drugs after 2
or 4 days of treatment (Figure 5) (i.e., compared with untreated cells).
In addition, treatment with the individual agents had little or no effect
on p21 expression, however. In comparison, EGCG plus taxane in-
creased the levels of p53, p73. and p21 by more than 5- to 10-fold
after 2 and 4 days of treatment, respectively (Figure 5). In sum, the
data suggest that increased apoptotic gene expression may be associated
with EGCG- and taxane-induced apoptosis.
TUNEL Assays to Assess Drug Effects on Apoptosis
The percent apoptosis was measured on histologic sections of tu-
mors using the TUNEL assay. Three tumors from each group of
mice treated with vehicle, EGCG, docetaxel, or both EGCG and
docetaxel for 0, 2, and 4 days were evaluated (Figure 6A). Relatively
few apoptotic cells were detected on day 0 (untreated tumors) and in
the vehicle-treated tumors on days 0, 2, and 4 (Figure 6A). A com-
paratively large number of apoptotic cells were present in the tumors
exposed to EGCG (i.e., >90 cells/field of view), docetaxel, and pac-
litaxel (>200 cells/field of view) on days 2 and 4 (Figure 6A). More
importantly, in tumors treated with EGCG and docetaxel or EGCG
plus paclitaxel, the combined treatment produced a significant in-
crease in the numbers of apoptotic cells (>500 cells/field of view)
in tumors treated for 2 and 4 days (Figure 6A).
Interestingly, we observed that in groups of mice treated with the
combination therapy, the mice were healthier and approximately
24% heavier overall than those treated with EGCG or taxane alone
(Table 1). Of particular interest is the transient weight loss caused by
using docetaxel alone, from which animals are protected by the use of
EGCG in combination with docetaxel (Table 1). Presumably, the im-
proved weight gain is related to the reduced tumor burden.
EGCG Combined with Paclitaxel Blocks Bone Metastases
by PC-3ML Cells
We have previously demonstrated that the injection of PC-3ML
cells i.v. through the tail vein results in bone marrow metastases in
CB17 SCID mice [9]. We have used this model to determine whether
EGCG plus paclitaxel delivered i.p. can block metastatic tumor
growth. Tumors were allowed to establish for 1 or 2 weeks before
Figure 3. Percent apoptosis by PC-3ML cells. PC-3ML cells (∼70% confluent) were treated with vehicle and increased dosages of EGCG
(i.e., 10, 30, and 50 μM), paclitaxel (6.25 nm), and docetaxel (3.12 nm) alone for 0 and 6 hours and 1, 2, 4, 6, and 8 days, respectively.
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beginning treatment with drug i.p. biweekly for 2 months. Data in
Figure 6B show that the numbers of mice with bone marrow tumors
decreased from 100% in untreated mice (n = 10/10 mice) to less than
10% to 30% (i.e., 1/10, 2/10, or 3/10) mice with tumors, depend-
ing on the cell number injected or whether they were allowed 1 week
versus 2 weeks to establish tumors before the onset of drug ther-
apy (Figure 6B). Next, we examined whether mouse survival rates
increased significantly after discontinuation of drug therapy. All
of the untreated mice died within 6 to 7 weeks after inoculation
(Figure 6C ). In comparison, after treating the mice with drug for
2 months, with the discontinuation of treatment for 3 months, most
mice survived (i.e., n = 8/10 and n = 7/10 mice survived) (Figure 6C).
Those that died were tumor-bearing mice, and they died within
∼3 weeks of stopping the drug treatments. Dissection and histology
Figure 5. Western blots of p53, p73, and p21 expression in ex-
tracts from freshly established PC-3ML tumors (i.e., 2 weeks after
inoculation of mice with PC-3ML cells). Mice were treated with
EGCG, paclitaxel, docetaxel, EGCG + paclitaxel (E + P), EGCG +
docetaxel (E + D) injected i.p. daily for 0, 2, and 4 days. Control
blots with β-actin antibodies. Drug concentrations were 200 μM
EGCG, 20 mg/kg paclitaxel, and 5 mg/kg docetaxel.
Figure 4. (A and B) In vivo efficacy of EGCG and taxane against established PC-3ML xenografts in CB17 SCID mice. (A) PC-3ML tu-
mor volume in mice treated with either vehicle, EGCG (200 μM, or 228 mg/kg), paclitaxel (20 mg/kg), or 200 μM EGCG and paclitaxel
(20 mg/kg) for 1 to 9 weeks. (B) PC-3ML tumor volume in mice treated with vehicle, EGCG (200 μM, 228 mg/kg), docetaxel (5 mg/kg), or
increased amounts of EGCG (100, 200, 300 μM) plus docetaxel (5 mg/kg). Tumor volumes were measured by sacrificing animals each
week (n = 3/time point/treatment). Drug was administered on a weekly basis i.p. starting on week 3 after inoculation of mice with PC-
3ML cells (1 × 106 cells/animal i.p.), and treatment was continued for 1 to 9 weeks. Data represent the mean ± SD of tumors found i.p.
in mice (n = 5/data point). (C) Mouse survival rates after treatment of mice for 8 weeks with EGCG (300 μM) plus docetaxel (12.5 mg/kg)
or paclitaxel (20 mg/kg) (see methods in B). After discontinuation of treatment, mouse survival was monitored for an additional 12 weeks
(n = 10 mice/treatment). Note: Control mice treated with EGCG or taxane alone failed to survive more than 1 to 2 weeks after treatment
(data not shown).
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examination of the bone marrows of the surviving mice indicated that
they were free of any detectable tumor burden in the lumbar verte-
brate, fibia, or soft organ tissues (i.e., muscle, lungs, liver, kidney,
gut, intestine, mesenchymal, brain, and heart tissues).
Discussion
The treatment of human prostate metastatic cancer remains a formi-
dable problem in as much as therapeutic advances have not signifi-
cantly improved clinical outcome. The utilization of EGCG as a
Figure 6. (A) Summary of data from TUNEL assays of apoptotic cells in tumors treated with vehicle, EGCG, docetaxel, paclitaxel, EGCG
plus docetaxel, and EGCG plus paclitaxel for 0, 2, and 4 days. Using a 40× objective, the numbers of apoptotic cells were counted in five
fields of view in three different tumors. Data represent the mean ± SD of numbers of apoptotic cells/field of view. Note: We avoided
counting apoptotic cells in areas of necrosis, but the necrotic areas were more prevalent in tumors treated with EGCG plus taxane than
in tumors treated with each agent alone. (B) PC-3ML cell metastases to the bone marrow in CB17 SCID mice. Mice (male mice, 8-
10 weeks of age) were injected i.v. via the tail vein with 1 × 104 and 1 × 105 PC-ML cells in 0.1 ml of DMEM. After 1 or 2 weeks, mice
were then treated with EGCG (228 mg/kg) plus paclitaxel (20 mg/kg) given i.p. biweekly. Mice were treated for 2 months and killed to
evaluate tumor metastases by gross dissection and histology. n = 10 mice/experiment. (C) Mouse survival rates after treatment. Mice
were injected with PC-3ML cells at 1 × 104 and 1 × 105 cells/ml in 0.1 ml for 2 weeks. Mice were untreated (empty bar) or treated with
EGCG + paclitaxel (solid bar) for 2 months according to methods in B. Then treatment was discontinued for 3 months before sacrifice of
the mice.
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therapeutic agent has shown considerable promise in clinical trials
[7,8]. In an earlier study, we found that EGCG alone was effective
in preventing tumor growth from PC-3ML cells in SCID mice [6].
However, total eradication of the tumors and/or reduction in the vol-
ume of established tumors was not possible [6]. In efforts to augment
the cytotoxic activity of EGCG, we have investigated a combination
therapy using paclitaxel and docetaxel. In this article, we have shown
that the combination therapy had a synergistic effect in decreasing
cell viability and inhibiting the growth of PC-3ML cells in vitro.
The combined drug treatment also increased apoptosis rates signifi-
cantly from less than 3% in untreated cells to more than 25% in
treated cells. More importantly, we found that the combination ther-
apy had a synergistic additive effect in blocking growth and eradi-
cating established tumors in mouse tumor modeling studies. A
significant increase in overall, disease-free mouse survival rates was
observed after treatment of mice harboring primary tumors (i.e.,
>90%) and metastatic lesions (>70%). The implication is that EGCG
combined with taxane might be used to treat patients with advanced
prostate cancer and metastatic disease.
From a clinical point of view, we also found that the combination
drug therapy helped maintain healthier animals, characterized by in-
creased body weight compared with groups treated with either agent
alone. Second, toxicology studies failed to show synergistic or addi-
tive toxicity from the combined use of docetaxel and EGCG (data
not shown).
Previous studies have shown that EGCG in combination with
doxorubicin has a synergistic or an additive effect in preventing tu-
mor growth in several cancer models [17]. Likewise, we have found
that localized delivery of relatively high doses of EGCG (228 mg/kg
or 200 μM) in combination with very low doses of doxorubicin
(<0.14 mg/kg or 2 μM) can either eradicate or significantly reduce
PC-3ML tumors growing i.p. in CB17 SCID mice [6]. Data showed
that EGCG promoted doxorubicin retention by the tumor cells to
increase efficacy. Consequently, it was feasible to treat mice fre-
quently with relatively nontoxic dosages of doxorubicin, thereby
increasing drug bioavailability and uptake by newly arising tumor
cells. However, in these studies, the tumors were relatively small
(<0.2 mm3) at the time treatment was initiated, and this may ex-
plain, in part, the success of the drug therapy. Other experiments
in this study showed that attempts to treat large established tumors
with EGCG and doxorubicin failed to eradicate the tumors [6], in-
dicating that higher dosages of doxorubicin were required or a better
drug combination was needed.
Green tea has previously been reported to have useful antioxidative
effects and to inhibit carcinogenesis [17–21]. The antitumor effects
of green tea are due to the components of green tea such as the cat-
echin group, the vitamin group, caffeine, and theanine [18–24].
Specifically, green tea contains ascorbic acid (vitamin C), several
B vitamins, riboflavin, niacin, folic acid, and pantothenic acid. Inter-
estingly, there have also been several reports showing that different
green tea components in combination with doxorubicin can block
tumor growth [24,25]. Nagata [24] and Sadzuka et al. [24,25] found
that theanine and caffeine inhibited doxorubicin efflux from Ehrlich
ascites tumor cells and that theanine rendered doxorubicin resistant
Ehrlich ascites tumors sensitive to doxorubicin and increased doxo-
rubicin suppression of metastasis. They suggested that flavonoids en-
hanced the doxorubicin-induced antitumor activity and increase the
doxorubicin concentration in tumors through the inhibition of doxo-
rubicin efflux [26]. Green tea extracts in combination with doxo-
rubicin also have been found to enhance the inhibitory effect of
doxorubicin on Ehrlich ascites tumors in mice [26]. Likewise, EGCG
was found to enhance the apoptotic effect of sulindac and tamoxifen
in tumor cells [27]. These studies failed to address where EGCG in
combination with a chemotherapeutic agent could eradicate estab-
lished tumors.
Overall, the data suggest EGCG is a relatively nontoxic agent that
can be used in combination with a chemotherapeutic drug to treat
cancer. EGCG has minimal toxic adverse effects because it does not
seem to accumulate in normal cells and tissue or to hamper their
survival. Neither does the high dosages given to mice seem to have
any toxic adverse effects (i.e., induce hair loss, neuropathy, serious
weight loss, and tissue damage). More importantly, EGCG seems
to readily accumulate in tumor cells and tumors, turning them brown.
EGCG’s primary activity is to block drug export, reduce tumor cell
viability, induce apoptosis, sensitize cells to apoptotic effects of chemo-
therapeutic drugs, and block the expression of genes essential for in-
vasion and metastases (i.e., MMP-2/9) [28,29].
Role of p53, p73, and p21 in Tumor Cell Apoptosis
More than 50% of all human cancers contain mutations in the
p53 tumor suppressor gene [30]. In response to cellular stresses such
as DNA damage and hypoxia, p53 is activated and can mediate cell
cycle arrest and apoptosis through the up-regulation of numerous tar-
get genes [31]. p21WAF1, a potent inducer of cell cycle arrest [32],
and Bax [33], initiators of the apoptotic cascade, are p53 target genes.
Interestingly, p53 probably does not work alone and undoubtedly has
partners with similar functional activities. One important clue was that
p53-null mice maintain normal embryonic development [34], sug-
gesting a family of closely related proteins with overlapping functions
must exist. Recently, two new genes, TP73 and TRP63, which en-
code p73 and p63 proteins, have been identified which exhibit struc-
tures and functions related to p53 (for reviews, see Levrero et al. [35]).
The first p53 homolog described was p73 [34], and p73 shares
considerable sequence identity with p53, reaching 63% within the
DNA-binding domain and including highly conserved DNA contact
residues frequently mutated in tumors [36]. Mechanistic studies in-
dicate that p73 can bind to the p53 consensus DNA-binding motif
and activate a number of p53-regulated genes, including p21WAF1
[37]. p73 can also induce cell cycle arrest and apoptosis [37]. The dif-
ferential regulation of p53 target genes by p73 indicates that, although
the activities of p53 and p73 overlap, these two proteins also main-
tain separate and unique functions within a cell [37]. In any event,
the data in this article clearly show that EGCG combined with taxane
can promote the overexpression of both p53 and p73 proteins in
PC-3ML cells and tumors. Specifically, we found that p53 levels in-
creased several fold in response to treatment with EGCG, thereby
increasing cell sensitivity to taxane-induced apoptosis. In response to
the combined drug therapy, there was more than two- to eight-fold
increases in p53 and p73 than those observed in cells treated with
either docetaxel alone or EGCG alone. These cells also exhibited more
Table 1. Relative Body Weight.
Week Vehicle EGCG Docetaxel (12.5 mg/kg) EGCG + Docetaxel
0 100 100 100 100
3 95.22 91.22 74.32 94.06
6 99.6 93.41 79.45 128.33
10 110.05 103.70 104.00 134.21
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than two-fold increases in p21 and caspase 3 levels and significant in-
creases in the percent apoptosis in vitro and in vivo. Most likely,
EGCG and taxane affect distinct yet complementary signaling path-
ways that promote the expression of genes involved in apoptosis
(i.e., p53, p73, p21, caspase 3) and cell survival. Further investigation
of the possible mechanism(s) modulating the synergistic activities of
EGCG and taxane is in progress.
In summary, we have developed a novel therapeutic strategy for
the treatment of prostate cancer with EGCG in combination with
conventional chemotherapeutic agents. This combination therapy
produced an additional therapeutic benefit over either individual mo-
dality. In particular, relatively low-dose taxane produced a synergistic
effect with EGCG, which suggests an important possible neoadju-
vant therapy for the treatment of prostate cancer. More importantly,
with the bone metastases studies, we found that treatment of mice
i.p. with the combination therapy reduced bone metastases and in-
creased mouse survival rates by more than 70% to 80%.
In conclusion, based on the preclinical mouse tumor modeling
studies presented here, we believe that EGCG might be effectively
used at high dosages delivered locally to increase the efficacy of taxanes
in eradicating highly aggressive and metastatic tumors in patients.
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